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Malaria is one of the leading causes of high infant morbidity & mortality in children aged 
five years and below in the sub-Saharan Africa. Emergence of resistance to all classes of antimalarial 
drugs is currently a huge challenge for the fight against malaria. Combination therapies of rapid and 
slow killing antimalarial drugs is the current first-line therapy to achieve complete parasite clearance 
or cure. The majority of previous laboratory-based malaria preclinical drug studies have relied on 
drug inhibition of low numbers of parasites numerically compared to untreated controls. In contrast, 
human malaria drug studies measure the decline or killing in high numbers of parasites numbering 
near a trillion per person. We therefore hypothesize that single dose or combination 
pharmacodynamics of Plasmodium drug killing in a high parasitemia in vivo mouse malaria model is 
different from parasite P. falciparum inhibition in vitro.  
We assessed the in vivo single dose dynamic killing pharmacodynamics properties of 
artesunate and 4-aminoquinolines (pyronaridine, chloroquine, and amodiaquine). Parasiticidal metrics 
employed were parasite log reduction, undetectable parasitemia duration, speed & duration to 
recrudescence (initial parasitemia) and 30-day cure in a PbergheiANKA-GFP-Luciferase-based murine 
malaria blood stage model that has an untreated parasite multiplication rate of a 9 fold increase over 
24 hours. Our model waits 4-days post infection for the 3-5% high parasitemia so that one can 
measure parasite clearance or log reduction. 
In this study, pyronaridine exhibited dose-independent killing, achieving parasite reduction 
near 5-6 logs at 48 hours post dosing with complete cure at 10 mg/kg compared to artesunate, which 
exhibited a 48 hour dose-dependent killing with a 2 log drop at the noncurative high dose of 250 
mg/kg. Chloroquine (noncurative) and amodiaquine (partially curative) have nearly the same initial 
dose-independent killing with a lag phase of no parasite reduction between 6 and 24 hours post 
dosing, but an 2.5 log reduction at 48 hours. In drug treated, washed infected blood transfer 




hour compared to 8 hour transfer measured by a prolonged return to parasitemia, despite a similar 
log reduction, in contrast to the correlation of parasite log reduction to viable parasites with 
artesunate and pyronaridine.  Artesunate in combination with pyronaridine exhibited a slightly weak 
antagonistic effect, while the combination with chloroquine or amodiaquine, showed an additive 
effect. Single oral dose pyronaridine was much more potent in vivo than artesunate, chloroquine and 
amodiaquine. 
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CHAPTER 1 - INTRODUCTION 
 
GLOBAL BURDEN OF INFECTIOUS TROPICAL DISEASES 
 
Infectious diseases occur and thrive in the tropical and subtropical regions such as the sub-
Saharan Africa and south-east Asia where the environmental conditions are humid and hot. Some of 
the tropical infectious diseases include: neglected tropical infectious diseases (NTDs), HIV/AIDS, 
tuberculosis and malaria. First, the NTDs, are communicable diseases that impact and predominate 
in the low-income poverty stricken & underprivileged regions with poor hygiene and sanitation 
measures in the tropical regions. According to WHO, NTDs prevail in 149 countries affecting more 
than a billion people globally and low-income countries are affected by at least five NTDs. This 
subset of tropical diseases has been neglected by researchers, policy-makers. NTDs are a subset of 17 
bacterial, protozoal, parasitic and viral infections including: human African trypanosomiasis (sleeping 
sickness), chagas disease, dengue & chikungunya, guinea-worm disease, echinococcosis, buruli ulcer, 
leishmaniasis, leprosy, lymphatic filariasis, rabies, food-borne trematodiases, schistosomiasis, soil-
transmitted helminthiases, trachoma, yaws, taeniasis and onchocerciasis. (Feasey N et al., 2010; 
Bhutta et al., 2014; Dye C 2014; Hotez PJ et al., 2004).  
Second, HIV & AIDS. Human immunodeficiency virus (HIV) can lead to disease known as 
the acquired immunodeficiency syndrome (AIDS) if left untreated. HIV virus attacks human host’s 
immune system, specifically the immune T cells known as CD4 cells that fight off infection, and 
drastically lowers the number of these immune cells hence weakening the host’s immune system 
making the victim vulnerable to many other opportunistic infections. AIDS is considered the worst 
stage of HIV infection when the host’s immune cells CD4 counts have dropped below 200 cells per 
cubic millimeter of blood, and/or they have acquired other opportunistic infections. HIV/AIDS is 
considered a sexually transmitted disease that can also be transmitted through infected body fluids 
such as blood, breast milk, and by sharing contaminated needles. HIV/AIDS is one of the greatest 
killers and public health challenge in the low and middle income countries (LMIC) around the World. 




to UNAIDS global HIV statistics: by the end of 2015 nearly 36.7 million people globally were living 
with HIV and of these 1.8 million were children below 15 years old, 1.1 million people died from 
AIDS-related illnesses, and worldwide new HIV infections was at 2.1 million people. As of mid-
2016, approximately 18.2 million people are receiving antiretroviral treatment globally. (UNAIDS 
2016; Bhutta ZA et al., 2014). 
Third, Tuberculosis (TB) is the second greatest killer in part due to HIV/AIDS infections, 
and one of the top 10 causes of death worldwide. Nearly 95% of TB deaths occur in the LMIC with 
highest burden in Asia and Africa. According to CDC and WHO reports, approximately one third of 
the world population is infected with TB. Of the estimated 2-3 billion people infected with TB only 
about 5-15% develop TB disease in their lifetime. Reports have shown that in 2015 nearly 10.4 
million people were infected with TB while 1.8 million others died from the disease. The 60% of all 
the TB-related deaths were mainly in Asia and African countries (South Africa, Indonesia, China, 
Nigeria, Pakistan, and China). [WHO]. TB is also the leading killer of the HIV patients and in 2015 it 
accounted for 35% of HIV deaths. However, due to the effective use of the antiretroviral therapy, 
the number of TB-related deaths among HIV patients fell by 32% since 2004. [UNAIDS 2016]. 
Interestingly, in 2015 the mortality rate was reported to be 47% lower than in the early 90’s and 
currently there are about 22 high TB burden countries accounting for the 80% TB cases worldwide. 
(UNAIDS 2016). Tuberculosis is an infectious airborne disease caused by the bacilli Mycobacterium 
tuberculosis (Mtb), a gram negative facultative intracellular bacteria that colonizes the lungs and 
airways, and can grow and replicate inside macrophages. Transmission of TB occurs via respiratory 
route when a person inhales and gets exposed to Mtb bacilli via airborne droplets exhaled through 
cough or sneeze from TB infectious individual. The inhaled bacilli deposit in the alveoli – air sacs in 
the lungs where they enter and multiply inside the alveolar macrophages. However, some of the 
bacilli escape the immune response and spread by the lymphatic or bloodstream channels to the rest 
of the lungs and other distant body tissues and organs. This rapid dissemination prime’s the host’s 




two kinds of TB: primary tuberculosis disease and Latent TB infection (LTBI). About one third of 
the world population has the latent tuberculosis. TB is both preventable, treatable and curable disease 
using the antimicrobial drugs majorly the isoniazid and rifampicin, however emergence of anti-TB 
drug resistance is one of the challenges facing fight against TB and has led to another form of TB 
known as the multidrug-resistant tuberculosis (MDR-TB) (Korb VC et al., 2016). 
Fourth, Malaria is also a major public health challenge and the great single tropical infectious 
disease killer of all time that continues to rob many lives, especially pregnant women and children 
under the age of five years old in sub-Saharan Africa and South-East Asia. Malaria has killed more 
than 30 million people since 1981 which was the start of the AIDS epidemic. The global burden of 
























GLOBAL BURDEN OF MALARIA 
 
Malaria History Overview 
 
Malaria has been the most ubiquitous infectious disease known for many centuries as a 
public health threat worldwide. Malaria has afflicted human race throughout the evolutionary age and 
history dating back to the ancient Egyptians and Greeks around B.C. Table (i) shared below briefly 
outlines the malaria history timeline and highlights some of the key malaria discoveries and events 
from pathogenesis, diagnosis, chemoprevention, vaccine, preventive measures as well as challenges 
experienced in fight against malaria such as development of drug resistance.  
Table (i): Malaria History Timeline 
Timeline Key Discoveries & Events 
30 million years’ 
old 
Fossils of mosquitoes shows malaria vector present before the earliest 
history 
2700 BCE  Malaria symptoms (periodic fevers) described in ancient Chinese 
medical writings. 
 Malaria became widely recognized in Greece by the 4th century 
BCE. Hippocrates noted the principal symptoms. 
 During 2nd century of BCE, in China the Qinghao plant (Artemisia 
annua) was described in medical treatise. 
284-363 BCE Ge Hong of East Yin Dynasty first describes anti-fever properties of and 
recommends Qinghao (Artemisia annua) effusion for alleviating malaria 
symptoms 
1631 Description of Quinine (Chinchona bark) in Peru and transport to Rome for 
malaria therapy. 
1820 Quinine was first purified from tree bark, which had been used to treat 
malaria for many years’ prior 
1874 German chemistry student, Othmer Zeidler, synthesized DDT for his thesis 
1880 Charles Louis Alphonse Laveran first identifies the malaria parasite. (He was 
awarded Nobel Prize in 1907 for the discovery). 
1886 Differentiation of species of malaria by Italian neurophysiologist known as 
Camillo golgi. He received Nobel Prize in 1906 for his work. 
1890 - 1931 Naming of human malaria parasites.  
 In 1890 the names Plasmodium vivax and Plasmodium malariae were 
first introduced by Italian investigators Giovanni Batista Grassi and 
Raimondo Filetti.  
 Alphonse Laveran, who was the first to observe parasites in a 
malaria patient’s blood, believed there was only one species known 




 In 1897 an American, William H. Welch reviewed the naming of 
human malaria parasites and he maned the malignant tertian malaria 
parasite P.falciparum  
 In 1922, John William Watson Stephens described the fourth human 
malaria parasites P.ovale 
 In 1931, Robert Knowles and Biraj Mohan Das Gupta first 
described P.knowlesi. however the first documented infection with 
P.knowlesi was in 1965. 
1891 Guttmann and Ehrlich describe the use of methelene blue against malaria, 
launching efforts for synthetic antimalarials and path eventually leading to 
Chloroquine. 
1897-1898 Discovery by Sir Ronald Ross that mosquitoes transmit malaria (He was 
awarded Nobel Prize in 1902 for his work).  
1898-1899 Discovery the transmission of human malaria parasites Plasmodium by Italian 
investigators led by Giovanni Batista Grassi.  
1934 Hans Andersag discover the antimalarial drug known as Chloroquine 
(Resochin) in Germany, which was only widely used after World War II.  
1939 Paul Hermann Muller tests the insecticide Dichloro-diphenyl-trichloroethane 
(DDT) in Switzerland. (He was awarded Nobel Prize in 1948). 
1946  Primaquine, only marketed anti-relapse agent for P.vivax, first 
synthesized in the USA. 
 Chloroquine finally recognized and established as an effective and 
safe antimalarial by British and USA scientists.  
1947 Commercialization and widespread use of Chloroquine 
1951 Malaria disease is eliminated in the United States 
1955 WHO launches Global Malaria Eradication Campaign, excluding sub-
Saharan Africa. 
1957 First documented case of resistance to Chloroquine reported. Late 1950’s 
Chloroquine resistance emerges on Thai-Cambodian border. 
1969 The malaria eradication efforts are halted. 
1970’s Chloroquine resistance documented on every continent with malaria 
1972 Artemisinin was isolated from Artemisia annua by Chinese chemist, Tu 
Youyou. (Derivatives of this extract are today’s most potent and effective antimalarial 
drugs.) 
1976 William Trager and JB Jensen grow malaria parasite in culture for the first 
time. This opened door for drug discovery and vaccine development.  
Late 1970’s Resistance to sulfadoxine-pyrimethamine (SP) emerges 
1989 The FDA approves the use of the antimalarial drug Mefloquine 
hydrochloride, brand name known as Lariam® by Hoffmann-LaRoche 
1992 Malaria vaccine candidate RTS,S is developed by GlaxoSmithKline and the 
Walter Reed Army Institute. Clinical trials started the same year.  





1996 Insecticide-treated bednets proven to reduce overall childhood mortality by 
20% in large in multi-country African study. 
1998  Roll Back Malaria partnership launched by WHO, UNICEF, UNDP 
and World Bank. Key goal: halving malaria incidence and mortality 
by 2010. 
 WHO adopts home management strategy for malaria; trained 
community volunteer health workers provide antimalarials in remote 
African communities. 
 
Late 1990’s Mefloquine resistance emerges in the Southeast Asia 
2000 UN general assembly adopts the Millennium Development Goals (MDGs) 
and set target to halt and begin reversing malaria incidence by 2015.  
2001 WHO prequalifies first fixed-dose Artemisinin combination therapy (ACT) 
known as Coartem® (Artemether/lumefantrine) for treatment of 
uncomplicated malaria caused by P.falciparum. ACT is recommended as first-
line malaria treatment. 
2002  The Global Fund to Fight AIDS, TB, and Malaria is established, led 
by UCSF’s Sir Richard Feachem. 
 Genome sequencing of malaria vector (Anopheles gambiae) and 
parasite (Plasmodium falciparum) is completed.  
2005 World health assembly adopts 80% worldwide coverage of insecticide nets 
and ACTs by 2010. 
2010 Prequalification of Artesunate injections for severe malaria by Guilin 
Pharmaceuticals 



















Morbidity & Mortality 
Malaria is a severe life-threatening killer disease in the tropical & subtropical regions 
especially in the sub-Saharan Africa where there is still huge burden of the disease. Estimated malaria 
mortality rates are highest in the endemic countries with lower gross national income per capita and 
nearly half of the world population is at risk of malaria. According to the 2016 world malaria report 
there were 212 million new cases of malaria worldwide in 2015, with African region accounting for 
almost 90% of the global malaria cases, followed by Southeast Asia region (7%) and the Eastern 
Mediterranean region (2%). The 2016 report further documents that there were approximately 
429,000 malaria deaths worldwide, with most of the deaths (92%) occurred in African region, 6% in 
South-East Asia region and 2% in Eastern Mediterranean region. Between the years 2010 and 2015, 
malaria incidence rates fell by 21% in African region and globally. In areas with high transmission, 
pregnant women and children below 5 years old are the most vulnerable groups and at high risk of 
malaria disease in the endemic populations; more than 70% of all malaria deaths occur in the 5 years 
and under age group, particularly susceptible to malaria morbidity, infection and death. In 2015, the 
disease killed approximately 303,000 children under five years of age globally. The greatest 
percentage-96% was from the African region (292,000 deaths). However, the report affirms that 
malaria mortality rate among children 5 years and below fell by 35% and overall, the malaria mortality 
rates also fell by nearly 31% in African region and by 29% globally between 2010 and 2015 among all 










MALARIA DISEASE LIFE CYCLE & TRANSMISSION 
 
 
Malaria is a life-threatening killer disease that is caused by the Plasmodium species parasites 
transmitted by the infected Anopheles spp. female mosquito vectors when they blood feed on human 
host. Human malaria is caused by P. falciparum and four other Plasmodium species that have also been 
recognized to be infect humans and these include P. malariae, P. vivax, P. ovale, and P. knowlesi. The 
human malaria life cycle involves two hosts: mosquito vector and human host. The human cycle 
entails the exo-erythrocytic cycle in the liver and the erythrocytic stage in the blood. One of the key 
bottleneck stages is the sporozoites infecting the liver. When the infected female mosquito vector 
takes blood meal it injects sporozoites, which then invade the hepatocytes (liver cells) and become 
invasive and slow down their movement speed. The majority of the sporozoites deposited do not 
reach the blood vessels, some die in the skin, while others are taken up by the antigen presenting cells 
Figure (i): Malaria Life Cycle. 




such as macrophages and others get into the drainage lymph nodes. Up to 10% of sporozoites 
transform into the merozoite stage in the liver and it is estimated that one sporozoite results into 
about 5000 to 10,000 hepatic merozoites. (Ijeoma and Sinnis 2009). Liver merozoites initiate the 
asexual blood stage (erythrocytic) by invading the erythrocytes (RBCs) forming ring stage – asexual 
haploid cell division, trophozoite, schizonts, merozoites, (another cycle of ring stage), and then 
gametocytes. The ring stage is only seen evidently in the peripheral circulation with the P. falciparum 
because this species is capable of infecting all RBC ages (both young and old), and the trophozoites 
cytoadhere on the endothelial cells via surface antigens to evade splenic clearance.  
The sexual stage takes place in the mosquito, also known as sporogonic cycle, begins when 
the female Anopheles mosquito blood feeds on an infected human host and ingests the Plasmodium 
gametocytes which are at a relatively low density in the blood meal compared to the density of 
asexuals in the human host. Then gametocytosis begins- macrogametes and microgametes fuse to 
form a zygote. The zygote develops into a motile ookinete that moves to the mosquito midgut and 
develops into oocysts, which is the other key bottleneck stage: the number of oocysts formed. The 
oocysts release sporozoites into the hemocoel, which traverse into the salivary gland.  
When the mosquito takes another blood meal, it injects the sporozoites from the salivary 
gland into the human skin. During blood meal, sporozoites are released from the salivary glands as 
mosquito probes and salivates in the human host and only stops when she finds blood. In the 
mosquito oocyst, the sporozoites have the highest insect density of Plasmodium parasites followed by 
the salivary gland sporozoites, with the lowest being those delivered into the human skin, where only 
1% reach the blood stream enroute to the liver. For the human host cell invasion, the Plasmodium 
parasite (sporozoites) uses gliding motility and cell traversal mechanisms during which the human 







MALARIA DIAGNOSIS AND PATHOGENESIS 
 
 Malaria disease diagnosis methods that have been employed thus far include clinical 
diagnosis and blood examination. Clinical diagnosis looking at key symptoms such as fever, 
splenomegaly and anemia are still being used in malaria endemic countries in sub-Saharan Africa but 
grossly over-estimates the infection. The blood examination diagnosis methods include the use of 
microscopy (blood films examination using Giemsa staining to detect malaria parasites), Rapid 
Diagnostic Tests (RDT) used for aldolase, lactate dehydrogenase and histidine-rich protein-2 (Hrp-2) 
detection, DNA – genomic detection using real-time PCR or nested PCR, RNA detection of asexual 
blood stages and gametocytes using reverse transcriptase real-time PCR, and using serology or 
ELISA for antibody detection. Microscopy use of blood films is considered the gold standard 
diagnosis tool however it has issues such as being very hard to visualize or distinguish specific 
parasite blood stages, it is time consuming and requires intensive training and practice. (WHO 2016 – 
Diagnostic Testing).  
Malaria diagnosis is both density and volume dependent. An RDT samples in the range of 10 
to 20 microliters of blood more than the 0.1 microliter sampled by microscopy even though both 
have nearly same sensitivity. Most of the RDTs accommodate maximum volume of up to 20 
microliters of whole blood , however it is not a quantitate test but rather gives a yes/no response on 
the presence of the P. falciparum. Also the malaria RDT cassettes come in different sizes and this 
affects the efficiency of the test. RDT is one of the current measures of malaria diagnosis that is 
much faster (provide rapid results within 15-30 minutes, are relatively simple to perform and 
interpret, and require very limited training on how to use) than microscopy which majorly relies on 
microscopes, well-trained technicians and the necessary reagents that are scarce resources in the 
malaria endemic areas. Rapid Diagnostic Testing (RDT) is readily available for use in malaria 
epidemics and emergencies though one of the problems facing this diagnosis test is the high 
asymptomatic parasitemia cases in most of the sub-Saharan Africa. However, the downside of RDT 




therefore only suitable for P. falciparum. WHO highly recommends use of RDTs for malaria diagnosis 
before initiating treatment. (WHO 2016, JHSPH – MMI 2015 Malariology Lecture on diagnosis).  
Classic Clinical Human Malaria 
This is the most lethal and killer version of the disease and it is associated with the asexual 
blood stage parasite cycle in the human host. The malarial parasite releases various toxic components 
inside the erythrocyte such as hemozoin (malaria pigment) and parasite proteins upon schizont 
rupture. These components exacerbate the disease by triggering the host’s immune cells 
(macrophages and other innate antigen presenting cells) to illicit symptoms such as fever, one of the 
clinical manifestation of malaria disease. The other symptoms are anemia due to hemolysis and 
enlarged spleen (splenomegaly), severe cases manifest severe anemia and cerebral coma. P. falciparum 
causes more lethal clinical disease because it infects both young and old RBCs, it has high 
amplification, causes end organ failure, and it undergoes through the process of sequestration. P. 
falciparum has the surface proteins (polymorphism and antigenic variation to evade the host immune 
response) such as the erythrocyte membrane protein PfEMP-1 expressed on the surface of the 
infected red blood cell and it therefore cytoadheres on the surface of host receptors expressed on the 
endothelial cells. The PfEMP-1 ligand accounts for the sequestration hence only the ring-stage of the 
parasite is detected within the circulation (periphery) and the mature stages are sequestered in the 
blood vessels such as the capillaries and other organs. (JHSPH – MMI 2015 Malariology Lecture on 
diagnosis). 
Asymptomatic Malaria 
It exists largely in the malaria endemic areas especially among the children and adult persons 
who have had repeated exposure to the disease. Mostly the asymptomatic malaria cases are untreated 
and clinically undetectable since people don’t feel sick or manifest the clinical symptoms as much, 
therefore most of the asymptomatic people don’t visit health clinics or seek medical attention. 




the Anopheles mosquitoes during blood meals and this extends the parasite’s life cycle when a new 
person is bitten by the infected vector mosquito. Asymptomatic malaria contributes largely to 
transmission and it can be detected using other measures such as doing blood surveys and slide 
positivity cross-sectional test within a community of both adults and young people to determine 
parasite prevalence. (Laishram DD et al., 2012; Snow RW et al., 2012; Chen I et al., 2016). 
Malaria Pathogenesis 
Malaria pathogenesis risk factors include mosquito vector, human host, the malarial 
parasites, and the ecological or environmental factors. Mosquito factors include the vector 
competence – the measure of the vector’s ability to be infected by and transmit the Plasmodium 
parasite. Therefore, the higher the vector competence and density (vectorial capacity) the higher the 
transmission. The human host factors include immunity response, genetics and age. Humans have 
developed selective factors such as genetic polymorphism like the sickle cell trait whereby the red 
blood cells acquire a sickle-shape that protects against P. falciparum malaria disease however this 
manifests into a serious disease, sickle cell anemia, in most of the malaria endemic areas in Africa. 
The host immune response antibodies are effective in fighting the sporozoites by binding on the 
circumsporozoite protein. Antibody protection inhibits mobility of parasite into skin-liver-
bloodstream, however it requires very high levels of antibody, high binding affinity and efficient 
immunological memory. Development of anti-parasite immunity in the malaria endemic areas where 
most adults and children are asymptomatic and serve as reservoirs, however infants and children five 
years and below have weaker immunity and therefore first couple of exposures to malarial parasite 
results into severe cases such as cerebral malaria, severe anemia, as well as death.  
Cerebral malaria is a case scenario of when the host immune system over-reacts (cytokine 
storm) to the infection and this worsens the disease. Some of the parasite factors include: species, 
strain and density. In the severe malaria cases most parasites are sequestered and cytoadhere on the 
endothelial cells. The Plasmodium species have differences and P. falciparum is the most virulent and 




into cerebral malaria, severe anemia. The parasite also has different strain differences and diverse 
surface antigens that undergo antigenic polymorphism to evade the host’s immune system. 
Environmental factors affecting transmission include space and time, different types of rainfall can 





















MALARIA CHEMOPREVENTION – ANTIMALARIAL DRUGS 
In malaria endemic areas some of the prevention measures that have been taken to reduce 
malaria transmission include using indoor residual spraying, insecticide impregnated bed nets, and 
application of repellants. However, along with all these measures malaria chemotherapy and 
prophylaxis is also essential. The key goal of treating uncomplicated and severe malaria disease is to 
prevent development of severe conditions reduce death rate and most importantly cure the disease. 
Currently chemotherapy of malaria depends on several drugs. Effectiveness of an antimalarial 
depends not only on the interactions between the drug and Plasmodium parasite but also on the drug 
and the host, more specifically on the pharmacokinetics and pharmacodynamics properties of drugs.  
Antimalarial agents are classified as: blood schizonticides that act on the asexual erythrocytic 
stages of the malaria parasite, tissue schizonticides that inhibit liver stages, hypnozoiticides 
preventing relapses in P. vivax and P. ovale malaria and gametocytocides mainly target the sexual stage 
gametocytes to prevent transmission from human to mosquito. In falciparum malaria, the blood 
schizonticides are considered sufficient to cure the infection. The currently well-known classes of 
antimalarials include artemisinin & derivatives, quinolines (4-aminoquinolines – chloroquine, 
amodiaquine, and new drug of interest pyronaridine, 8-aminoquinolines such as primaquine and new 
drug tafenoquine), antifolates (proguanil, sulfadoxine, pyrimethamine) and antibacterials (atovaquone, 
doxycycline). (WHO).  
Artemisinins & Derivatives 
Artemisinin and its derivatives are currently considered the most potent antimalarial agents 
and they have been efficacious in both uncomplicated and severe falciparum malaria. Besides 
artemisnin, the other derivatives developed include artesunate, artemether, dihydroartemisinin, 
arteether, which are currently considered the most effective antimalaria drugs to treat against human 
falciparum malaria. Artemisinin was discovered in China by Dr. Tu Youyou, who won the Nobel 




sweet wormwood plant (Artemisia annua), where the drug is present in the leaves and flowers of this 
plant. The artemisinin structure was elucidated in 1979 and this enabled the development of 
derivatives. (Balint GA. 2001; Meshnick SR. 2002; Golenser J et al., 2006).  
Artemisinin and its derivatives are endoperoxide-containing products and schizonticidal 
gametocytocidal drugs that targets the infected red blood cells from late ring to trophozoites and also 
gametocyte stages, destroying the sexual erythrocyte stages of the Plasmodium parasite and preventing 
further transmission to the mosquito during blood meal. Studies both preclinical and clinical have 
shown that artemisinin and derivatives are potent anti-malarial drugs that are effective against malaria 
parasites and multi-resistant strains (Li Q and Weina P. 2010) and achieve faster parasite clearance, 
even though they are short-lived. Artemisinin compound’s mechanism of action involves activation 
by the heme iron or free iron which generates radical damage of nearby proteins, lipids and enzymes. 
Other observations on artemisinin action are lack of inhibition for heme crystallization, inhibition of 
the calcium ion transporter PfATPase6, interaction with the malaria protein Histidine-rich protein, 
increase in lipid damage and generation of carbon centered radicals without damage by oxygen 
radicals (Meshnick, SR 1998; Li Q et al., 2007).  
Some of the pharmacological properties of artemisinin and derivatives are as follows: they 
have shorter biological or elimination half-life than aminoquinolines and the peak plasma 
concentrations are reached in about 1 to 2 hours. Of the derivatives, artesunate acts as the prodrug 
since it is rapidly converted into its active metabolite dihydroartemisinin (DHA) that accounts for 
artesunate’s antimalarial activity. Artesunate’s pharmacokinetic properties make it the most effective 
artemisinin compound currently used in ACTs for the oral treatment of uncomplicated malaria. (Lee 
IS, Hufford CD 1990). 
The artemisinin & derivatives’ route of administration varies, some are administered orally, 
intravenously or intramuscularly. Oral formulations are absorbed rapidly but incompletely. 




rapidly in either route of administration in contrast to other artemisinin derivatives. Studies have 
shown that artesunate administered intravenously is more effective for the treatment of both severe 
and complicated malaria and have reported that injectable administration of artesunate results in 
more systemic availability than the other artemisinin derivatives. (Li Q et al., 2007, de Vries & Dien 
1996). For the treatment of severe malaria, currently WHO recommends use of the injectable 
intravenous or intramuscular artesunate for at least twenty-four hours followed by complete 3-day 
course treatment of Artemisinin Combination Therapies (ACTs). For adults and children above 6 
months old, WHO recommends oral administration dose regimen of 5 mg/kg artesunate orally first 
day followed by 2.5 mg/kg second and third days in combination with mefloquine 15 mg/kg on the 
third day. WHO recommends the following dose regimen for the parenteral administration after 
dissolving the artesunate powder in 5% sodium bicarbonate: loading dose of 2 mg/kg followed by 1 
mg/kg after 4 hours and 24 hours (total of 4 mg/kg). The currently recommended total therapeutic 
dose regimen range of artesunate-amodiaquine combination is 4 mg/kg body weight per day 
artesunate and 10 mg/kg body weight per dose amodiaquine free base. (WHO guidelines for 
treatment of malaria 3rd Edition). No major clinical toxicity manifestations have been seen in people 
except extreme cases such as neurotoxicity in murine malaria models such as mice. Adverse effects 
are typically mild with artemisinins including headache, dizziness, and weakness in adults, rare 
hypersensitivity reactions. (China Research Group 1982, Brewer TG et al. 1994). 
One of the key drawbacks of artemisinin compound therapy besides recrudescence and 
being costly, is the emergence of delayed clearance or resistance to artemisinins. Artemisinin delayed 
clearance in P. falciparum first emerged and was reported in western Cambodia characterized by slow 
or delayed parasite clearance – reflecting reduced susceptibility of the ring stage parasites. Both in vitro 
and in vivo studies have identified molecular markers of artemisinin resistance and reported that 
mutations in the Kelch 13 (k13)-propeller domain are associated with the delayed parasite clearance. 





The 4-aminoquinolines belong to the overall quinoline class of antimalarial drugs and these 
include chloroquine, amodiaquine and pyronaridine. 4-aminoquinolines were the first synthetic class 
of the quinoline antimalarials to be used in treatment of malaria and chloroquine became the key 
agent of malaria therapy for at least four decades and most successful in clinical use until today due 
to resistance problems. During the World-War II period, chloroquine emerged as one of the active 
and least toxic quinoline derivatives given as 150 mg free base (60%) or 250 mg/kg tablet. (Hoekenga 
et al., 1952; O’Neil PM et al., 1998). It has been reported that chloroquine acts by interrupting 
hematin detoxification in the Plasmodium parasite as it grows inside the human host’s RBC (Chou AC 
et al., 1980, 1998; Sullivan et al., 1996; Dorn A et al., Wellems & Plowe 2001).  
Chloroquine 
Chloroquine was discovered as alternative against quinine, which was considered malaria 
wonder drug for quite a long time, for both treatment and prophylaxis of malaria. However it was 
heavily and widely used south-east Asia and sub-Saharan Africa leading to chloroquine resistance 
problems in both P. falciparum malaria endemic regions. Chloroquine resistance was first detected in 
the Cambodia-Thailand Southeast Asia and Colombia South America in the 1950s before worldwide 
spread. In Africa, resistance was first detected in Kenya and Tanzania in 1970s, even though there 
was still quinine use at the moment, still malaria morbidity and mortality spiked up especially among 
children. In falciparum malaria, chloroquine resistance is linked to multiple mutations in PfCRT 
protein that functions as a transporter of unknown function in the parasite’s digestive vacuole 
membrane. (Wellems & Plowe 2001). Even though resistance to chloroquine reduced its clinical use, 
it is still used in special patient groups such as children and pregnant women, for treatment of 
nonfalciparum malaria and as a comparator for in vitro and in vivo preclinical testing of new 





According to WHO, chloroquine is a 4-aminoquinoline that has rapid schizontocidal activity 
against blood stages of P. ovale, P. malariae and against susceptible strains of P.vivax and P. falciparum. 
Chloroquine is currently used for acute malarial attacks – P. malariae and P. falciparum susceptible 
infections – and for prophylaxis for pregnant women and non-immune persons at risk, however, its 
use is prohibited in the chloroquine-resistant malaria regions. The recommended dose regimen by the 
WHO, (all dosage are described in terms of free base) and as follows: oral dose administered to 
adults, children and pregnant women given at 10 mg/kg on the first day then 5 mg/kg six to 8 hours 
later, and 5 mg/kg on day 2 and 3 in a single dose (total dose of 25 mg/kg). The parenteral 
administration is only considered in no resistance situations or if the patient is unable to take drug 
orally. According to CDC malaria treatment information: uncomplicated falciparum malaria acquired 
in areas without chloroquine resistance, a dose regimen of chloroquine 600 mg base (1000 mg salt) is 
to be given initially followed by 300 mg base (500 mg/kg salt) at 6, 24 and 48 hours post initial dose 
(total of 1500 mg base ~ 2500 mg salt). For prophylaxis in adults and pregnant women give 300 mg 
base weekly and children 5 mg/kg weekly. Absorption is efficient following oral administration and 
peak plasma concentration occur within 2 to 3 hours and it can be detected in the plasma and urine 
for up to 2 months and 4 months respectively upon single dose administration. Adverse effects are 
rare except for rare hypersensitivity and minor headaches based on the dose regimen taken or 
recommended. (CDC 2016, WHO 2016).  
Amodiaquine 
Amodiaquine is another 4-aminoquinoline that is structurally related to and has mode of 
action like chloroquine and it is also active against asexual Plasmodium stages. Amodiaquine was 
synthesized in 1946 and first introduced as an alternative antimalarial due to its effective activity 
against the chloroquine-resistant falciparum parasites. However, currently highly chloroquine-
resistant falciparum is also resistant to amodiaquine. (Beshir K et al., 2010). In vitro studies have 
shown that amodiaquine and chloroquine mode of action is by inhibiting hemozoin crystallization 




(Famin & Ginsburg 2002, German & Aweeka 2008). Currently amodiaquine is only recommended 
for treatment and not prophylaxis against malaria. This is owing to the rare but serious adverse 
effects such as hepatitis and agranulocytosis resulting from its long-term use. Amodiaquine was 
therefore re-introduced into the malaria chemotherapy and currently used as a partner drug for the 
artemisinin combination therapy with the short-lived Artesunate. The WHO recommended dosage is 
10 mg/kg free base (13.5 mg/kg salt) (salt form is amodiaquine dihydrochloride) daily for 3 days 
usually in combination with other agents. (WHO 2016, Hoekenga et al., 1952). Combination therapy 
of sulfadoxine-pyrimethamine with amodiaquine has been reported to be efficacious regimen for 
intermittent preventive treatment to prevent malaria in children (IPTc) however the amodiaquine 
component is not always well tolerated. (Kerb R et al., 2009). Clinical studies in multicentered phase 
III trials have shown that the artesunate-amodiaquine combination therapy was more efficacious 
than amodiaquine monotherapy explored in African children, however cases of neutropenia were 
reported. (Adjuik M et al., 2002; Ndiaye JL et al., 2009). 
Like chloroquine, amodiaquine is also administered orally and it is rapidly absorbed from the 
GI tract and undergoes rapid metabolism in the liver to N-desethyl-amodiaquine (DEAQ) that 
concentrates in the blood cells. Studies have reported that amodiaquine concentration in the blood is 
low however it is more potent than its metabolite, it is the DEAQ that’s responsible for most of 
antimalarial activity. P. falciparum in vitro studies comparing both amodiaquine and its metabolite 
reported that amodiaquine enhanced DEAQ’s efficacy and therefore showed a synergistic activity. 
Researchers are still investigating on other amodiaquine metabolites such as N-bis-desethyl-
amodiaquine and 2-hydroxydesethylamodiaquine. (Winstanley et al., 1987; Mariga ST et al., 2004; 
Giao & de Vries 2001).  
Even though clinical trials and studies have shown that artesunate-amodiaquine combination 
treatment as efficacious for uncomplicated P. falciparum malaria, some of the adverse effects associate 




agranulocytosis, hepatotoxicity, asymptomatic neutropenia and acute dystonic reaction to name a few 
(Winstanley PA et al., 1990). Some studies have suggested that toxicity with amodiaquine is directly 
dose-dependent besides involvement of host’s immune response; while others have also reported 
that amodiaquine’s reactive quinoneimine metabolite as the key toxic agent that triggers anti-
amodiaquine IgG antibody-based immunological response. (Rhodes EG et al 1986, Rouveix B et al 
1989).  
Pyronaridine 
Recently, 4-aminoquinoline derivatives closely related to chloroquine and amodiaquine are 
shown to have potency even against CQ resistant strains of parasites (Kaschula CH et al., 2002; 
Raynes KJ et al., 1999). Pyronaridine, which is amodiaquine-like compound, was developed in China 
is now a marketed drug which has been through clinical trials for the combination therapy with 
artesunate (Ringwald P et al., 1996; Deshpande and Kuppast 2016). Pyronaridine (Malaridine), a 
benzonaphthyridine derivative, was first synthesized in China in 1970 where it has been used as 
antimalarial single agent for malaria treatment for nearly more than three decades ago, however it has 
very limited use in the rest of the world where malaria is endemic. Recently interest has been renewed 
in pyronaridine as a possible partner drug for ACT therapy and therefore it is considered an 
investigational drug for a fixed-dose combination with artesunate (3:1 ratio) for treatment of 
uncomplicated falciparum malaria and also blood stage vivax malaria. The investigational ACT is 
under the trademark known as Pyramax. (European Medicines Agency 2015; Ramharter M et al., 
2008; Zheng XY et al., 1979, 1982].  
Pyronaridine chemical formulae is as shown (4-[(7-chloro-2-methoxybenzo[b][1,5] 
naphthyridin-10-yl)amino]-2,6-bis[(pyrrolidin-1-yl)methyl] phenol). Pyronaridine is composed of a 9-
aminoacridine (mepacrine) and amodiaquine-like structure (Chanc C et al., 1992; Chang YC et al., 
2001). The salt form of the drug is known as pyronaridine tetraphosphate which constitutes about 




as a tablet, intramuscularly in liquid form, and also via intravenous route. There are different versions 
of the drug in form of capsule formulation (100 mg and 50 mg free base), capsule fixed dose with 
Artesunate (3:1) coated tablet (Shao BR et al., 1990; Ramanathan S et al., 2005). The currently 
administered human dose in combination with artesunate (3:1) is 4 tablets of 180 mg pyronaridine 
tetraphosphate salt and 60 mg artesunate. This is 12 mg/kg of pyronaridine tetraphosphate and 4 
mg/kg of artesunate each day for three days. Pyronaridine tetraphosphate salt is soluble in water 
(allows for effective oral absorption) while the free base is very sparingly soluble in water and it is 
more liposoluble than the salt. (Adegoke OA et al., 2006). 
As a 4-amnioquinoline, pyronaridine acts by inhibiting heme crystallization. Studies have 
shown that pyronaridine interferes with the Plasmodium food vacuole of the late trophozoites and 
schizonts (Wu LJ et al., 1988; Kawai S et al., 1996). Other in vitro studies have also shown that it 
targets haematin formation by inhibiting beta-haematin formation with similar IC50 of 0.125 uM as 
chloroquine (Auparakkitanon S et al., 2006). Moreover, more studies have reported that pyronaridine 
inhibits glutathione-dependent haem degration (Auparakkitanon S et al., 2006; Famin O et al., 1999). 
More investigations are on-going to fully elucidate on its mechanism of action. Studies using murine 
models have indicated that pyronaridine has potent activity against malaria asexual stages. Other 
studies have used the primate models to investigate on the schizontocidal activity of this 4-
aminoquinoline and it was found efficacious against P. inui in rhesus monkeys. (Ye XY et al., 1990; 
Looareesuwan S et al., 1996).  
Cross-resistance with chloroquine and other antimalarials studies have been done and it was 
determined that pyronaridine is more potent than chloroquine against P. falciparum and chloroquine-
resistant isolates in vitro though this has been inconsistent (Childs GE et al., 1988; Ringwald P et al., 
1996, Pradines B et al., 1999). Not clearly elucidated is the mechanism by which resistance to 
pyronaridine develops. However, a study shown that rodent P. berghei ANKA slowly developed 




passages) however higher doses were more effective at selecting for resistance (Shao BR et al., 1986). 
In vivo resistance with combination therapy – researchers have derived pyronaridine-resistant P. 
berghei and P. yoelii strains by in vivo serial passage and shown delayed development of resistance in P. 
berghei versus pyronaridine alone (Peters W et al., 1992, 1999, 2000). These results are encouraging as 
they indicate that pyronaridine plus artesunate may retard the development of resistance. Resistance 
in clinical isolates from China where pyronaridine has been used for more than three decades now as 
both combination therapy and monotherapy, data has shown the potentiality of resistance developing 
but at a slower pace in spite of chloroquine resistance. Other studies have shown that the 
combination therapy of pyronaridine and other antimalarials potentially reduces pyronaridine 



















ANTIMALARIALS PHARMACODYNAMICS / KINETICS 
 Pharmacodynamics is the action of the antimalarial drugs against the Plasmodium parasites. 
Pharmacokinetics is how the body handles or responds to the drug. Pharmacokinetics-
Pharmacodynamics (PK-PD) are some of the key determinants of a therapeutic response. The 
antimalarial drugs’ speed of response in killing the parasites mirrors the rate at which the disease is 
controlled (White NJ 2013). Therefore, understanding the PK-PD of each antimalarial class will help 
with effective optimization of the drug dosage and quantitate therapeutic response. Currently, 
treatment of malaria relies on the combination therapies, even though effective dose, schedule and 
duration of the combination regimens is yet to be fully determined or elucidated. The PK-PD models 
have been used to help describe the parasitemia time-course in the malaria human patients and 
animal models before, during and post treatment with the antimalarial regimens given in combination 
or as monotherapy [Gordi T et al., 2005]. The ACTs have not been formulated based on suitable 
matching PK and PD profiles to improve efficacy and delay or prevent resistance. (WHO 2011).  
Studies have been done to assess the pharmacokinetics and pharmacodynamics of the 
antimalarial agents individually looking at the drug’s mechanism of action, clinical pharmacology – 
absorption, distribution, metabolism, elimination, and clinical pharmacodynamics. Studies have 
assessed PK properties of chloroquine, a 4-aminoquinoline, and found that it is well absorbed from 
the gastrointestinal tract and tissues, it is extensively distributed in the tissues such as liver, kidney, 
spleen, lung and melanin-containing tissues, it is nearly 60% bound to plasma proteins, it is 
metabolized to desethylchloroquine and chloroquine alone accounts for nearly more than 50% of 
urinary products while the metabolite accounts for only 25%. Chloroquine’s elimination half-life has 
been reported to be in the range of 3 to 5 days while the terminal half-life is 30 to 60 days. [Brunton 
et al., 2010, Lexi Comp 2013].  For the clinical pharmacology, chloroquine is now resistant to P. 
falciparum in the malaria endemic countries but it still maintains activity against some strains and it has 
been found to be mostly effective against the asexual stages of P. vivax, P. ovale and P. malariae. 




Amodiaquine has also been found to be well absorbed from the gastrointestinal tract, the 
distribution volume range from 20-40 L/kg, it is metabolized to monodesethylamodiaquine though 
more metabolites are still being discovered, its elimination follows first order kinetics mean range of 
5-8 hours for amodiaquine and 9-18 days for desethylamodiaquine. Amodiaquine is currently given in 
combination with artesunate as one of the recommended ACTs by the WHO since it is active against 
chloroquine-resistant strains. (Brunton et al., 2010; Giao PT and de Vries PJ 2001). 
Artesunate, an endoperoxide, which is currently the first-line recommended partner drug for 
ACTs, has a shorter half-life compared to the 4-aminoquinolines and it is also rapidly metabolized to 
its active metabolite known as dihydroartemisinin (DHA) that concentrates in the infected 
erythrocytes, artesunate absorption is not affected by food and it is about 43-82% bound to plasma 
proteins. Elimination studies have also suggested that less than 1% of the drug is recovered as parent 
drug in urine, feces and bile. Artesunate oral bioavailability is about 15% compared to intravenous 
route and the half-life is nearly 2.7 minutes post intravenous administration while reported value for 
its metabolite DHA is about 40 minutes after oral or intravenous routes. (Brunton et al., 2010; Giao 
PT and de Vries PJ 2001, Morris CA et al., 2011).  
Pyronaridine, which is currently considered the most interesting 4-aminoquinoline for the 
ACTs, needs further extensive pharmacological studies on its PK / PD properties. It might be 
considered as first-line for treatment of uncomplicated malaria in the endemic regions with 
chloroquine-resistance. Clinical studies have assessed pyronaridine’s pharmacokinetics and found that 
intramuscular dose is absorbed with Tmax 0.66 hours and Cmax 525 ug/L while Tmax post oral 
administration of 600 mg salt was 5 to 14 hours (Fu S 1991; Chang C et al., 1992), and it has a 
terminal half-life of about 64 hours. Other studies such as the Sang & Pradeep 2009 assessed the 
absorption, distribution, excretion and PK properties of pyronaridine tetraphosphate using rat 
models. This group found that following oral administration of single dose 10 mg/kg salt the drug 




tissues with drug peak in blood was reached at 8 hours post administration. This group also found 
that the excretion of the drug was through urine at peak excretion post 24 hours of administration, 
the Cmax, AUC and Tmax values were similar to those observed in the clinical phase II trials of 
artesunate-pyronaridine conducted in Uganda. The plasma parameters post dosing with the 10 
mg/kg pyronaridine salt were Cmax 189-207 ng/ml, Tmax 7-8 hours, half-life 148-157 hours (6-6.5 
days) and AUC240hr was about 14 ug.hg/ml while at infection was about 20 ug.hg/ml. The blood 
parameters were nearly similar to the plasma parameters. [Park SH 2010; Davis CB et al., 2008).  
Pharmacokinetics assesses the time course of the antimalarial drug and its effects in the 
body, besides it also allows for the quantification of absorption, distribution, metabolism and 
excretion post taking the drug. These are some of the processes that help determine the drug 
concentration in the body, for instance, in whole blood and in plasma. An effective dosage regimen is 
determined by the concentration of the antimalarial drug in the body. Drug concentrations are mostly 
measured in whole blood, plasma and serum besides other body fluids. The measured drug 
concentrations are referred to as drug levels, the total drug concentration (both bound and unbound 
drug in equilibrium). The concentration of the drug in the plasma is not usually the same as the 
concentration in different organs and tissues.  There are different pharmacokinetic models as 
described herein. The unimodal response is whereby the drug achieves a homogenous distribution 
throughout the body and then it equilibrates in all the tissues. This concentration-time profile would 
show a log linear correlation. The bimodal and multimodal response is when the drug does not 
achieve distribution in the different organs and tissues in the body instantly, hence the concentration-
time profile would show a curve with initial rapid decline in concentration and then it flattens out – 
equilibrates to other different tissues. The rapid decline in concentration is due to distribution to 
other tissues and organs as well as elimination from the body. (Winter 2003; White & Garrison 1994).  
The pharmacokinetics parameters in human models have shown that the 4-aminoquinolines 




and 5.52-17.1 L/h/kg respectively. Both amodiaquine and chloroquine have been shown to have oral 
bioavailability of nearly 90% while artesunate 15-32 %. (Table ii). Chloroquine has been shown to 
have a large volume of distribution (100-1000 L/kg) compared to artesunate which has zero volume 
of distribution. (Table ii).  






























80-90 >90 17-38 5.52-17.1 2-10 Monodeset
hyl 
Winstanley 
PA et al., 
1987 
Chloroquine 
(300 mg oral) 
80-90 50-64 100-1000 0.1-0.78 40-55 Mono/bis 
desethyl 
De Vries et 
al., 1994; 




19-32 >65 71 0.72 64 None Chang C et 
al., 1992; Fu 
& Xiao 
1991 
Key Reference article: Giao PT and de Vries PJ. 2001. Pharmacokinetic Interactions of Antimalarial Agents. 
Clin Pharmacokinet 40 (5): 343-373. 
 
Besides looking at the pharmacokinetics parameters in humans (Table ii), other studies have 
also assessed the plasma and whole blood concentration-time profiles of artesunate and the 4-
aminoquinolines using rodent models (Figure ii).  Studies assessing the PK parameters for 
pyronaridine salt 10 mg/kg administered orally to rat models have reported nearly the same 
parameters in whole blood and plasma concentration-time profiles. These findings were nearly 
similar to findings observed in clinical phase II trials in humans. (Park SH 2010; Davis CB et al., 
2008). Studies that assessed artesunate and its metabolite dihydroartemisinin (DHA) administered in 
rats at 36 mg/kg intravenously showed that for both artesunate / dihydroartemisinin (DHA) the 
concentration declined faster and near complete elimination was achieved within 3 to 6 hours post 
administration however in clinical studies have reported much shorter half-life (nearly 3 minutes) 




concentration level ranging between 100-1000 ng/ml in both the whole blood and plasma which 
allows for their long-acting activity post administration. The 4-aminoquinolines are widely distributed 
throughout the body compared to artesunate/DHA. For instance, chloroquine and amodiaquine 
shows a bimodal response in the concentration-time profiles with a sharp drop followed by slow 
decline. (Figure ii). 
For the quinolones there is confusion in dosing on amount of salt and base given which can 
lead to under or overdosing adults and children. Table (iii) shows the normal adult total daily dose 
and total dose over three days for artesuanate and the quinolones. These daily doses can be 
converted to a mg/kg for pediatric dosing and conversion for animal or rodent doses which are 
allometrically equivalent to human dosing. In general when converting a human mg/kg dose to 
mouse it is necessary to multiply by a factor of 12 such that a 10 mg/kg human dose with 



















Figure (ii): Plasma (A) and Whole Blood (B) Concentration-Time Profiles for artesunate, 
pyronaridine, chloroquine and amodiaquine in murine models. 
 













AS 36 mg/kg rat IV Plasma
DHA 36 mg/kg rat IV Plasma
Pyr 10 mg/kg rat oral plasma
CQ 10 mg/kg rat oral plasma
CQ 50 mg/kg base mice oral plasma
CQ 20 mg/kg rat oral serum























AS 36 mg/kg Rat IV Plasma
DHA 36 mg/kg IV Plasma
Pyr 10 mg/kg rat oral Plasma
CQ 10 mg/kg rat oral plasma
CQ 50 mg/kg base mice oral plasma
CQ 20 mg/kg rat oral serum
























AS 36 mg/kg rat IV plasma
DHA 36 mg/kg rat IV plasma
Amq 30mg/kg rat i.p whole blood
Pyr 10 mg/kg rat oral whole blood
CQ 20 mg/kg rat oral whole blood























AS 36 mg/kg rat IV Plasma
DHA 36 mg/kg rat IV Plasma
Amq 30mg/kg rat IP whole blood
Pyr 10 mg/kg rat oral whole blood
CQ 20mg/kg rat oral whole blood








































































artesunate 240 240 720 720 4 4 48 48
pyronaridine 
tetraphosphate 400 720 1200 2160 6.7 12 80 144
chloroquine 
diphosphate 600* 1000* 1500 2500 10 16.6 120 200
amodiaquine 
dihydrochloride 600 790 1800 2370 10 13.2 120 160




CHALLENGE, RATIONALE, HYPOTHESIS & AIMS 
Challenge 
 
Humans with a 4% parasitemia have about one trillion parasites (4 million erythrocytes per 
microL of blood or a 4 trillion per liter times 6 liters times 0.04 parasitemia = one trillion infected 
erythrocytes per adult). Human malaria chemotherapy can be measured by a parasite reduction per 
time interval such as the 48 hour single P. falciparum life cycle. The artemisinins are postulated to 
provide a 4 log killing rate each 48-hr parasite cycle, quinolines with a 3 log killing rate, antifolates 
with 2 logs and antibacterials with a single next cycle (delayed generational) 1 log kill rate (Nicholas 
White 2004). In contrast to this parasite reduction measurement in humans, drug screening in vitro 
with P. falciparum starts with more than a billion times less parasites (about 100 thousand) to compare 
percent inhibition with untreated drug control which increases about 10-100 fold at 72 hrs. Parasites 
that slowly increase a log with untreated parasites increasing 2 logs have 90% inhibition. Most mouse 
models of drug activity commonly utilize the Peters suppression test which delivers a low parasite 
inoculum of parasites followed by high daily doses of drugs commencing hours after infection (W 
Peters 1974).  The murine malaria suppression tests inoculates 500,000 to 1 million parasites followed 
immediately by high drug doses. Parasite number at 4 days on drug is compared to no drug controls 
which multiply by a log each day or by about 4 logs in 4 days. If drug treatment results in a slower 
growth at only 2 logs in 4 days, this is expressed as 99% inhibition even if the parasites have 
multiplied.  
The majority of previous laboratory based malaria drug studies have relied on drug inhibition 
of low numbers of parasites numerically compared to untreated controls. In contrast, human malaria 
drug studies measure the decline or killing in high numbers of parasites numbering near a trillion per 
person. Therefore, for this thesis research I have adapted a murine malaria model utilizing a 
luciferase reporter rather than blood film counting to measure the decline in parasitemia after single 
drug dosing as a measure of killing compared to starting parasite number rather than inhibition 





The previous malaria drug screening efforts mostly focused on the inhibition assays done in 
vitro and in vivo, low parasite inoculum, high drug dose and comparison to no-drug control. Now my 
work mainly focuses on the newer pharmacodynamics killing assay with a high parasitemia burden 
and clinically relevant drug dosing to measure speed of drug response in killing parasites, which is 
important to quantitate therapeutic responses with different antimalarials. 
Hypothesis 
Single dose or combination therapy pharmacodynamics of Plasmodium drug killing in a high 
parasitemia in vivo model is different from parasite inhibition in vitro. 
Research Aims 
 
Aim 1: To compare single oral dose dynamic killing with Artesunate and 4-Aminoquinolines 
(Pyronaridine, Chloroquine, Amodiaquine).  
Aim 2: To measure 8 hour, 24 hour and 48 hour killing by the long half-life 4-
aminoquinolines in an infected blood transfer experiment where long exposure quinolone drugs are 
washed away. 
Aim 3: To investigate combination killing profiles with single dose 4-aminoquinolines 
(chloroquine, pyronaridine and amodiaquine) and Artesunate. 
The pharmacodynamic parasiticidal metrics employed are parasite log reduction, 
undetectable parasite killing duration, speed & duration to recrudescence (initial parasitemia) and 30-
day cure. The outcome of this work is a novel ranking of malaria drugs by parasiticidal properties 
rather than inhibition properties. This thesis work will also validate the model as a potential higher 
throughput model for drug killing, which is not readily measurably achievable with P. falciparum in 
culture (RD Young 1993). We argue that P. falciparum in vitro inhibition assays are not killing studies. 
We therefore hypothesize that kinetics and synergy of killing will be different from inhibition studies 





CHAPTER 2 – METHODOLOGY 
 
Antimalarial Drug Preparation 
The antimalarial drugs artesunate and the 4- aminoquinolines-pyronaridine, chloroquine and 
amodiaquine were obtained from Sigma Aldrich. The quinoline salts used were pyronaridine 
tetraphosphate (MW = 910 and 56% free base), chloroquine diphosphate (MW = 515 and 62% free 
base) and amodiaquine dihydrochloride (MW = 464 and 76% free base). Artesunate is 100% parent 
drug. For all the experiments, the quinolines were dosed in salt form. The conversion of the base / 
salt weight percentage is shown on table (iv) indicating the actual measurement of free base in the salt 
dosage employed and showing the mouse and human dose equivalents. Artesunate was dissolved in 
5% sodium bicarbonate, pyronaridine tetraphosphate, chloroquine diphosphate and amodiaquine 
dihydrochloride were each dissolved in deionized water (dH2O). Fresh drug solution was used for 
each experiment. Each drug solution was dosed at volume of 200 µL per mouse. 
Parasiticidal in vivo Murine Malaria Model 
All the experiments were done under the approved protocol MO15H319 by the Johns 
Hopkins University’s Animal Care and Use Committee. The rodent model used for all the 
experiments were Balb/cj female mice from the Jackson Laboratories aged at least 6 weeks old and 
weighed approximately 20 grams each. A replicate of three mice were used for each drug dose 
regimen tested.  
Infection with Plasmodium berghei ANKA GFP-Luciferase strain 
P. berghei ANKA, 676m1cl1, Green fluorescence protein-luciferase (PbANKA GFP-Luc) 
obtained from ATCC (catalog # MRA-868) constitutively expresses the luciferase at all stages in the 
life cycle. The PbANKA GFP-Luc clone enables 4-8 hour precise measurements of parasite 
dynamics over a 3 log range in a IVIS Spectrum Imager using the plate reader function. For each 
experiment Balb/cj female mice were infected via intrapetroneal (i.p) with a 10,000 infected 
erythrocytes from donor mouse in the first or second passage. The isolate obtained from the BEI 




were then exsanguinated, aliquoting infected blood for low (less than three) passage number in all 
experiments. Parasitemia in the experimental mice was monitored using Giemsa-stained thin blood 
film counting and luciferase measurements until approximately 3 to 4 % parasitemia was reached 
before initiating drug dosing - translating to millions of parasites per microliter as will be described in 
the luciferase assay protocol below. 
Parasite Monitoring 
Initial single (or multi) dose drug treatment with artesunate and the 4-aminoquinolines 
begins on day four (0-hr with high density parasitemia-millions parasites per microliter) post 
infection. Blood was withdrawn at 0-hr, 3-hr, 6-hr, 12-hr, 24-hr time-points within the first day post 
dose and followed up every day for 30 days post dose or until initial starting parasitemia was reached 
upon which mice were euthanized following the standardized protocol at the animal facility situated 
at the Johns Hopkins School of Public Health.  
Luciferase Reporter Assay 
Our murine malaria model utilizes a luciferase reporter assay rather than blood film counting 
to measure the decline in parasitemia after drug dosing. Luciferase reporter assay is a cell-based assay 
that analyzes the intracellular infection mechanisms of the parasite before and after drug treatment. 
The Plasmodium expressed firefly luciferase catalyzes luciferin oxidation using ATP-Mg2+ as co-
substrate. After the enzyme and substrates combine, a flash of light is generated and decays rapidly. 
The assay yields linear results over at least 4 orders magnitude. The assay is also comparable to the 
Giemsa staining in that it also measures the total number of parasites present at different end-points 
and it enables more time points than blood film counting.  
Blood Sample Collection 
For the blood sample collection, 5 µL of mouse tail blood is plated into 45 µL lysis buffer in 
a white round bottom 96 well plate stored at -80C (Lysis buffer reagents: 20mM Tris (pH 7.5), 5mM 
EDTA, 0.008% (wt/vol) saponin, and 0.08% (vol/vol) Triton-X-100) (Franke-Fayard B 2008). Then 5 µL 




and 95 µL of the luciferase buffer was added (1:20 ratio of blood sample in lysis buffer to the FLAR 
reagents) then the luciferase activity was measured in the IVIS Spectrum In Vivo Imaging system 
then analyzed using the Living Image v.4.4 software to get the total flux (photon per seconds). Our 
model begins to dose drugs four days after infection with high parasitemia translating to billions of 
parasites per mouse (approximately 10% parasitemia) and which will measure malaria metrics: drug 
speed of parasite killing, length of undetected parasitemia, duration & speed of recrudescence (return 
to initial parasitemia) and 30-day cure.  
Blood Transfer Experiment 
Balb/cj female mice were infected with PbANKA-GFP-Luc were dosed with specific single 
and multi-dose regimen of 4-aminoquinolines and artesunate respectively. Blood transfer time-points 
done were 0-hr, 8-hr, and 24-hr for all the drugs tested. Additional blood transfers done specifically 
for pyronaridine drug salt 50 mg/kg (30 mg/kg free base) were: 4-hr, 48-hr and 72-hr. At each 
transfer time point, 100 µL (tail blood) of the infected blood was withdrawn from each treated donor 
mouse and diluted in 1000 µL sterile PBS solution. The blood solution was then washed thrice with 
1000 µL sterile PBS by centrifugation (r.c.f. 3000 xg). After the third wash the infected erythrocytes 
were suspended in a final volume of 210 µL and 5 µL was placed in 45 uL lysis buffer for 
quantification of transferred cells using luciferase assay. Two-hundred microliter was injected via i.p 
into uninfected mice in order to effectively lower drug concentration below minimal inhibition to 
determine cell viability. The following malaria metrics were followed: parasitemia growth curves, time 
to parasite number of 10,000 and 100,000 parasites per microliter post each transfer, duration of 
undetected parasitemia (below limit of quantification 1000 parasites / µL) and time to starting 
parasitemia to compute number of killed parasites. Dilution curve of untreated infected mice at time 








All the data analyses and representations were performed with Graph Pad Prism 5 Software. Data are 
represented as mean ± SEM. The luciferase raw data log 10 total flux (photons/sec) was transformed 
to parasites per microliter using equation Y = (10^((log(y)-0.55)/0.05))*2 (Walker & Sullivan, 2017). 
All data were normalized to geo-mean starting parasitemia of 5 million parasites per microliter. 
Parasite log reduction (Pi – Pt) was achieved by getting the difference between Log10 of initial 
parasitemia (6.7) and parasitemia at time-point (t) – 6-hr, 12-hr, 24-hr and 48-hr. The statistical 
methods employed include the following: Two-Way ANOVA and / or t-test (non-parametric) were 
used for comparing two groups. For groups more than two, One-way Analysis of Variance 
(ANOVA) with Turkey Multiple comparison post-hoc test were used for comparison of groups as 
appropriate with alpha significance level p < 0.05. 
Table (iv): Mouse doses and human equivalents of artesunate and 4-aminoquinolines  
Antimalarial Drug Mouse Dose reference 
body weight 20 gm 
(Free Base) 
Human Dose Equivalent 
reference body weight 60 kg, 
multiply mouse dose by 0.081 
factor (Free Base) 
Artesunate 10 mg/kg  0.8 mg/kg 
 50 mg/kg  4 mg/kg  
 100 mg/kg  8 mg/kg 
 250 mg/kg  20 mg/kg 
Chloroquine diphosphate 10 mg/kg           (6) 0.8 mg/kg       (0.5) 
 50 mg/kg          (30) 4 mg/kg          (2.5) 
 100 mg/kg        (60) 8 mg/kg           (5) 
 250 mg/kg       (150) 20 mg/kg        (12) 
Amodiaquine dihydrochloride  10 mg/kg           (8) 0.8 mg/kg       (0.6) 
 50 mg/kg          (40) 4 mg/kg            (3) 
 100 mg/kg        (75) 8 mg/kg            (6) 
 250 mg/kg       (190) 20 mg/kg         (15) 
Pyronaridine tetraphosphate 1 mg/kg           (0.6) 0.08 mg/kg     (0.05) 
 2.5 mg/kg        (1.5) 0.2 mg/kg       (0.11) 
 5 mg/kg            (3) 0.41 mg/kg     (0.23) 
 7 mg/kg            (4) 0.57 mg/kg     (0.32) 
 10 mg/kg           (6) 0.8 mg/kg        (0.5) 
 50 mg/kg          (30) 4 mg/kg           (2.2) 
 100 mg/kg        (60) 8 mg/kg           (4.5) 
 150 mg/kg        (90) 12 mg/kg         (6.8) 
 250 mg/kg       (150) 20 mg/kg         (11) 
Reference: [USFDA 2005]. Human equivalent dose calculation factor obtained from FDA draft guidelines. 
FDA: Food and Drug Administration, HED: Human equivalent dose. Nair AB, Jacob S. A simple practice 
guide for dose conversion between animals and human. J Basic Clin Pharma 2016;7:27-31. The value in 




CHAPTER 3 – RESULTS 
 Artesunate exhibits dose-dependent killing in a single oral dose regimen.  To 
investigate the single dose dynamic killing with artesunate, we tested dose regimen escalation at 10 
mg/kg, 50 mg/kg, 100 mg/kg and 250 mg/kg in a PbANKA-GFP-Luc infection. The six and 12 
hour log reduction was similar except 10 mg/kg regardless of the dose at about 1 log reduction in 
this short time period. In contrast the 24 and 48-hr measurement show a clear progressive larger log 
reduction with increasing artesunate dose.  The human dose of 4 mg/kg is equivalent to 50 mg/kg in 
mice and just showed a single log reduction at the full 24-hr cycle in P. berghei. The duration to return 
in initial parasitemia was also progressive with increasing doses and no cure. (Figure 1a, Table 1a). 
Pyronaridine exhibits dose-independent killing in a single oral dose regimens. 
Pyronaridine, a 4-aminoquinoline, was also tested at 10 mg/kg, 50 mg/kg, 100 mg/kg and 250 
mg/kg given as pyronaridine tetraphosphate salt (Figure 1b, 2a).  Pyronaridine exhibits dose-
independent killing and completely cures at all doses (Figure1a). While the doses for pyronaridine are 
based on the total salt, the active molecule, the free base is 56% of the salt, which almost doubles the 
potency (Table (ii) in methods). Parasite log reduction at 6 hours was similar to artesunate at 1 log 
reduction but by12 hours post dosing was measured near 2 log reduction. At 24 hours post dosing, 
there was a large 3-4 log reduction increasing to nearly 5 - 6 log drop at 48 hours post dosing. (Table 
2b). All the mice (n=3) in each of these dose groups were completely cured at 30 days. 
Chloroquine and amodiaquine exhibits initial dose-independent killing in a 
single oral dose regimen. Chloroquine and amodiaquine, also 4-aminoquinolines, were tested 
with a dose regimen administered at 10 mg/kg, 50 mg/kg, 100 mg/kg and 250 mg/kg  based on salt 
weight (chloroquine base is 62% of salt; amodiaquine base is 76% of salt ). Chloroquine and 
amodiaquine show a plateau phase after an initial 6 hour drop from 6 to 24 hours post dosing with 
an approximate single log reduction the first 24 hours no matter the dose from 10 to 250 mg/kg 
(Figure 1c-d). Mice dosed with 50-250 mg/kg showed a further dose independent ~3 log parasite 




reversing. (Table 1c-d). Measure of duration to return to initial parasitemia was dose-dependent 
taking nearly 3- 9 days for mice to return to initial parastemia with increasing doses, a reflection of 
longer drug exposure time. Two of three mice achieved complete cure with amodiaquine 250 mg/kg. 
Single oral low dose pyronaridine at 10 mg/kg or below is more potent than 
artesunate administered in a total dose of 150 mg/kg and 600 mg/kg sustained over 
24 hours in a 3-dose regimen. We were interested in comparing the single dose killing dynamics 
of low dose pyronaridine 1-10 mg/kg to artesunate given in three dose regimen of 50 mg/kg every 8 
hr totaling 150 mg/kg and also 200 mg/kg every 8 hr  totaling 600 mg/kg given at time-points 0, 8 
and 16 hours post initial dose, respectively (Figure 2a,b). Artesunate has a short 6-8 hour exposure in 
the mouse, so testing a multiple dose regimen over 24 hours creates a sustained drug level 
comparable to the quinolines. Pyronaridine at single dose of 1 mg/kg showed no reduction. 
However, 5 mg/kg and 7 mg/kg had nearly 1 log kill at 24 hours and nearly 2 log kill at 48 hours 
post initial dosing. Indeed the 5 mg/kg pyronaridiine dose was similar to the 250 mg/kg artesunate 
single dose in Figure 1a. Two of three mice with single dose pyronaridine at 7 mg/kg achieved 
complete cure. However, single dose pyronaridine at 10 mg/kg was most potent with nearly 3 log kill 
at 24 hours and 5 log kill at 48 hours, almost twice the log drop seen with 5 mg/kg and 7 mg/kg, 
post initial dosing. (Table 2a). All the mice dosed with 10 mg/kg pyronaridine were cured. Mice that 
received 3-dose regimen of artesunate at 200 mg/kg a dose (600 mg/kg total) (Figure 2b) showed a 
rapid reduction in parasites with a log reduction of 3 and 5 similar to as single dose 10 mg/kg 
pyronaridine at 24 hours and 48 hours post initial dose, respectively. (Table 2b). The duration to 
return in initial parasitemia with low dose pyronaridine was dose-dependent from 3 to 11 days.  The 
50 mg/kg each dose (150 mg/kg total dose) also showed a large log reduction in parasite numbers 
with 2 logs at 24 and 3.5 logs at 48 hours more comparable to the pyronaridine numbers. 
 Following single dose dynamic killing profiles we were interested in investigating on the 
measure of 8-h and 24 hours killing by the long-half life 4-aminoquinolines and short half-life 




below minimal inhibition. In this experiment, (Figure 3a-c) pyronaridine 50 mg/kg shows a linear 
correlation between the parasite log drop and duration it takes to reach 100,000 viable parasites post 
transfer at hours 4, 8, 24, 48 and 72 respectively. Both low dose (50 mg/kg) and high dose (150 
mg/kg) pyronaridine treated blood took nearly the same number of days to reach viable parasites 
post 8-and 24 hour transfers and nearly same mean parasite log reductions. Only two mice came up 
positive during 48-hours transfer and one mouse during 72-hours transfer. (Figure 3a) Artesunate 
given in multi-dose regimen took nearly five days post 24-h transfer to reach viable parasites. Multi-
high dose artesunate resulted in increased parasite log reduction almost below limit of quantification 
at 24-hrs and it took nearly 5 days to reach viable parasites post transfer into uninfected mice. (Table 
3).  High dose AS at 24-hour transfer took nearly the same amount of days to reach viable parasites 
as single dose pyronaridine 50 mg/kg at 48-hour transfer. (Figure 3b). Chloroquine and amodiaquine 
at both 50 mg/kg single oral dose had nearly the same parasite log reduction at both 8 and 24 hours 
post dosing in the treated donor mice and the duration to reaching viable parasites post dilution 
transfer was not that different, took about 1 and 2 days post 8 and 24 hours transfers respectively. 
(Figure 3c, Table 3).  
Effect of single dose dynamic killing in combination therapy with artesunate 
and 4-aminoquinolines. We were interested in investigating on the effect of single dose 
combination therapy with artesunate and pyronaridine, chloroquine and amodiaquine administered at 
50 mg/kg each in the combination regimen (Figure 4a,b,c). Dose of 50 mg/kg is the mouse 
equivalent to 4 mg/kg artesunate administered in humans. 
Artesunate-pyronaridine combination (Figure 4a), Artesunate 50 mg/kg alone had 
parasite log reduction of 1 log kill over 24 hours post dosing. At 24 hours and 48 hours post dosing, 
pyronaridine’s parasite log reduction was 4 times and 6 times that of artesunate 50 mg/kg alone. 




smaller log kill at all time points past 12 hours. (Table 4a). Mice dosed with pyronaridine 50 mg/kg 
alone and in combination with aretesunate 50 mg/kg were all cured.  
Artesunate-chloroquine or amodiaquine combination (Figure 4b), In contrast to 
pyronaridine, chloroquine or amodiaquine and artesunate were additive in the interaction when 
dosed together. There was no plateau phase in combination killing observed between 6 and 24 hours 
compared to single dose chloroquine 50 mg/kg alone. Mice dosed with combination regimen at 50 
mg/kg showed decrease in parasites slightly below the limit of quantification on day 3 then return to 
initial parasitemia nearly 6 days post initial dose (Table 4b,c). The artesunate-chloroquine 
combination therapy was not curative however there was a slight prolongation of duration to return 
to initial parasitemia.  
Comparing the combination drugs together in a single graph shows for the first 24 hours all 
have a similar 2 log reduction which slowed the next 24 hours with amodiaquine, was approximately 
2 again for chloroquine and continued to a 5 log reduction at 48 hours for the pyronaridine 
combination. (Figure 4d, Table 4d). 
Effect of increasing artesunate dose in a single dose combination therapy 
with long-acting 4-aminoquinolines. We were then interested in further comparisons of the 
effect of increasing the artesunate dose to 250 mg/kg while keeping the quinolines at 50 mg/kg to 
compare to 50 mg/kg for both combinations.  Artesunate 250 mg/kg via i.p alone had parasite log 
reduction of 2 log kill and nearly 4 log kill at 24 hours and 48 hours post dosing respectively. 
However, single oral dose pyronaridine 50 mg/kg had almost twice artesunate’s log kill at 24 hours 
and 6 log kill at 48 hours post dosing. Interestingly, in combination regimen with artesunate the 
parasite log reduction at time-points 6, 24 and 48 hours post dosing was similar to that of artesunate 
250 mg/kg alone (figure 5a). This clearly shows presence of slightly weak antagonism effect. Mice 
dosed with combination therapy and single pyronaridine 50 mg/kg alone were all cured. The 
combination of chloroquine or amodiaquine and high dose artesunate had a similar log reduction 




compared to chloroquine, amodiaquine or artesunate alone at nearly about 5 days (table 5b and c). 
Both chloroquine and amodiaquine displayed an additive effect of the drug combination on the rate 
of kill and delay in return to initial parasitemia. Interestingly, single oral dose pyronaridine 50 mg/kg 





















Figure 1(a): Single Oral Dose Killing Profile of Artesunate in a P.bergheiANKA-GFP-
Luciferase infection. Single dose artesunate dose regimen of 10 mg/kg, 50 mg/kg, 100 mg/kg and 
250 mg/kg was administered orally to Balb/cj female mice (n=3) at time 0-hr which corresponds to 
~ 10% parasitemia confirmed by Giemsa blood film counting. Data is represented as mean ± SEM. 
One-way analysis of variance (ANOVA) p-value summary *p-value<0.05.  
 






















10 1 0.5 0.5 0.2 -0.1 1.5 0 
50 1 0.9 0.9 1.0 0.4 2.5 0 
100 1 1.2 1.2 1.3 1.1 3.2 0 
250 1 1.0 1.0 1.5 1.8 3.5 0 
 
 












AS 10 mg/kg n=3
AS 50 mg/kg n=3
AS 100 mg/kg n=3



















Figure 1(b): Single Oral Dose Killing Profile of Pyronaridine in a P.bergheiANKA-GFP-
Luciferase infection. Single dose pyronaridine tetraphosphate salt dose regimen of 10 mg/kg, 50 
mg/kg, 100 mg/kg and 250 mg/kg was administered orally to Balb/cj female mice (n=3) at time 0-hr 
which corresponds to ~ 10% parasitemia confirmed by Giemsa blood film counting. Data is 
represented as mean ± SEM. One-way analysis of variance (ANOVA) p-value >0.05 
 
Table 1 (b): Measure of Parasite Log Reduction and Duration to Return to initial 





















10 1 1.3 1.9 3.4 5.1 CURE 3/3 
50 1 1.4 2.4 4.0 6.1 CURE 3/3 
100 1 1.2 2.5 3.7 5.8 CURE 3/3 
250 1 0.8 1.9 2.8 4.9 CURE 3/3 
 












Pyr 10 mg/kg ; n=3
Pyr 50 mg/kg ; n=3
Pyr 100 mg/kg ; n=3

















Figure 1(c): Single Oral Dose Killing Profile of Chloroquine in a P.bergheiANKA-GFP-
Luciferase infection. Single dose chloroquine phosphate salt dose regimen of 10 mg/kg, 50 mg/kg, 
100 mg/kg and 250 mg/kg was administered orally to Balb/cj female mice (n=3) at time 0-hr which 
corresponds to ~ 10% parasitemia confirmed by Giemsa blood film counting. Data is represented as 
mean ± SEM. One-way analysis of variance (ANOVA) **p-value <0.001  
 
Table 1 (c): Measure of Parasite Log Reduction and Duration to Return to initial 





















10 1   1.2      1.1 ** 3 0 
50 1 0.6 0.9 0.9 2.5 4.8 0 
100 1 1.0 0.9 1.2 2.7 6.8 0 
250 1 0.7 0.8 0.9 2.5 9 0 
 












CQ 10 mg/kg n=3
CQ 50 mg/kg n=3
CQ 100 mg/kg n=3



















Figure 1(d): Single Oral Dose Killing Profile of Amodiaquine in a P.bergheiANKA-GFP-
Luciferase infection. Single dose amodiaquine dihydrochloride salt dose regimen of 10 mg/kg, 50 
mg/kg, 100 mg/kg and 250 mg/kg was administered orally to Balb/cj female mice (n=3) at time 0-hr 
which corresponds to ~ 10% parasitemia confirmed by Giemsa blood film counting. Data is 
represented as mean ± SEM. ANOVA **p<0.001, ***p<0.0001. 
 
Table 1 (d): Measure of Parasite Log Reduction and Duration to Return to initial 





















10 1   1.1 2.5 4 0 
50 1 0.9 1.1 1.1 3.1 7 0 
100 1 0.7 1.0 0.9 3.1 11 0 
250 1 0.6 0.9 0.7 2.5 Partial Cure 2/3 
 












Amq 250 mg/kg m2
i.P
LQ
Amq 10 mg/kg n=3
Amq 50 mg/kg n=3
Amq 100 mg/kg n=3
Amq 250 mg/kg m1


















Figure 2 (a): Single Oral Dose Killing Profile of Low Dose Pyronaridine in a 
P.bergheiANKA-GFP-Luciferase infection. Single dose pyronaridine tetraphosphate salt regimen 
of 1 mg/kg, 2.5 mg/kg, 5 mg/kg, 7 mg/kg and 10 mg/kg was administered orally to Balb/cj female 
mice (n=3) at time 0-hr which corresponds to ~ 10% parasitemia confirmed by Giemsa blood film 
counting. Data is represented as mean ± SEM. 
 
Table 2 (a): Measure of Parasite Log Reduction and Duration to Return to initial 


















1 1 - 0.3 - 0.2 - 0.3 0.01 0 
2.5 1 0.1 0.7 0.3 2.6 0 
5 1 0.7 1.3 1.8 6.8 0 
7 1 0.6 1.4 1.9 Partial Cure 2/3 
10 1 1.3 3.4 5.1 CURE 3/3 
 














Pyr 1 mg/kg n=3
Pyr 2.5 mg/kg n=3
Pyr 5 mg/kg n=3
Pyr 7 mg/kg n=3















Figure 2 (b): Killing Profile of Artesunate 3-Dose Regimen in a P.bergheiANKA-GFP-
Luciferase infection. Three dose regimen of 50 mg/kg and 200 mg/kg were administered 
intrapetroneally to Balb/cJ female mice (n=3) at time-points 0-hr, 8-hr and 16-hr. Time 0-hr 
corresponds to ~ 10% parasitemia confirmed by Giemsa blood film counting. Data is represented as 
mean ± SEM. Two-Way ANOVA *p-value<0.05. 
 
Table 2 (b): Measure of Parasite Log Reduction and Duration to Return to initial 


















50 3 (q 8hr) 0.5 1.7 3.5 8 0 
200 3 (q 8hr)  3.3 5.5 15 0 
 












AS 150 mg/kg (50 x3) 0-8-16 hr n=3

















Figure 3 (a-c): Measure of 8-h and 24-h killing by the long half-life 4-aminoquinolines and 
short half-life artesunate in an infected blood transfer dilution. (Right) The treated donor kill curve 
post dosing with drug regimen (mean ± SEM). (Left) Scatter plot comparing parasite log reduction to 
days it takes to reach viable parasites post transfer (represented as individual mouse).  
           
                              
                   
 












Pyr 50 mg/kg n=3
i.P
LQ





















4-h Pyr 50 mg/kg n=3
8-h Pyr 50 mg/kg n=3
24-h Pyr 50 mg/kg n=3
48-h Pyr 50 mg/kg n=2
72-h Pyr 50 mg/kg n=1
8-h Pyr 150 mg/kg n=3
24-h Pyr 150 mg/kg n=3





















































8-h AS 200 mg/kg n=3 24-h AS 600 (200*3 q8hr) n=3





















































8-h CQ 50 mg/kg n=3
24-h CQ 50 mg/kg n=3
8-h Amq 50 mg/kg n=3
24-h Amq 50 mg/kg n=3






































Parasite Log reduction at Transfer Injection 
Transfer 8-hr  24-hr  
Drug (mg/kg) Mouse 1 Mouse 2 Mouse 3 Mouse 1 Mouse 2 Mouse 3 
Pyr 50  3.17 2.41 2.65 3.83 3.67 4.19 
Pyr 150  2.51 2.21 2.49 5.92 4.41 4.57 
AS 200*3 q8hr 2.25 1.22 1.69 3.30 3.04 2.95 
CQ 50  1.56 1.28 1.13 1.48 1.70 1.36 
Amq 50 0.94 1.10 0.97 1.80 2.21 1.45 
Transfer Pyronaridine 50 mg/kg Parasite Log Reduction 
4-hr 3.02 3.07 3.10    
48-hr 5.20 5.28     




Figure 4 (a): Effect of Single Dose Combination Therapy with Artesunate and Pyronaridine 
in a P.bergheiANKA-GFP-Luciferase infection. Single dose regimen of 50 mg/kg pyronaridine 
tetraphosphate salt and 50 mg/kg artesunate was administered orally to Balb/cJ female mice (n=3) at 
time-point 0-hr which corresponds to ~ 10% parasitemia confirmed by Giemsa blood film counting. 
Data is represented as mean ± SEM. One-way analysis of variance (ANOVA) **p-value<0.001 *p-
value<0.05 
 





















Artes 50 0.9 0.9 1.0 0.4 2.5 0 
Pyr 50 1.4 2.4 4.0 6.1 CURE 3/3 
AS + Pyr 50 + 50 1 1.4 2.2 4.8 CURE 3/3 
 














Pyr 50 mg/kg n=3
AS 50 mg/kg + Pyr 50 mg/kg n=3

















Figure 4 (b): Effect of Single Dose Combination Therapy with Artesunate and Chloroquine 
in a P.bergheiANKA-GFP-Luciferase infection. Single dose regimen of 50 mg/kg chloroquine 
phosphate salt and 50 mg/kg artesunate was administered orally to Balb/cJ female mice (n=3) at 
time-point 0-hr which corresponds to ~ 10% parasitemia confirmed by Giemsa blood film counting. 
Data is represented as mean ± SEM. One-way analysis of variance (ANOVA) *p-value <0.05. 
 























Artes 50 0.9 0.9 1.0 0.4 2.5 0 
CQ 50 0.6 0.9 0.9 2.5 4.8 0 
AS + CQ 50 + 50 0.9 1.4 1.9 2.3 6.8 0 
 












CQ 50mg/kg + AS 50mg/kg n=3
i.P
LQ
CQ 50 mg/kg n=3

















Figure 4 (c): Effect of Single Dose Combination Therapy with Artesunate and Amodiaquine 
in a P.bergheiANKA-GFP-Luciferase infection. Single dose regimen of 50 mg/kg (oral) 
amodiaquine dihydrochloride salt and 50 mg/kg (i.p) artesunate was administered orally to Balb/cJ 
female mice (n=3) at time-point 0-hr which corresponds to ~ 10% parasitemia confirmed by Giemsa 
blood film counting. Data is represented as mean ± SEM. One-way analysis of variance (ANOVA) 
*p-value<0.05. 
 
Table 4 (c): Measure of Parasite Log Reduction and Duration to Return to initial 





















Artes 50 0.9 0.9 1.0 0.4 2.5 0 
AMQ 50 0.6 1.1 1.1 3.2 8 0 
AS + AMQ 50 + 50   1.9 3.7 10 0 












Amq 50 mg/kg + AS 50 mg/kg n=3
LQ
i.P
Amq 50 mg/kg n=3














Figure 4 (d): Effect of Single Dose Combination Therapy with Artesunate and 4-
aminoquinolines in a P.bergheiANKA-GFP-Luciferase infection. Single dose regimen of 50 
mg/kg 4-aminoquinoline salt and 50 mg/kg artesunate was administered orally/i.p to Balb/cJ female 
mice (n=3) at time-point 0-hr which corresponds to ~ 10% parasitemia confirmed by Giemsa blood 
film counting. Data is represented as mean ± SEM. One-way analysis of variance (ANOVA) *p-
value<0.05. 
 
Table 4 (d): Measure of Parasite Log Reduction and Duration to Return to initial 
parasitemia. ANOVA *p<0.05 




















AS 50 0.9 0.9 1.0 0.4 2.5 0 
AS+Pyr 50+50 1 1.4 2.2 4.8 CURE 3/3 
AS+CQ 50+50 0.9 1.4 1.9 2.3 6.8 0 
AS+AMQ 50+50   1.9 3.7 10 0 
 
 












AS 50mg/kg + CQ 50 mg/kg n=3
i.P
LQ
AS 50 mg/kg + Pyr 50 mg/kg n=3 AS 50 mg/kg n=3















Figure 5 (a): Effect of Increasing Artesunate Dose in a Single Dose Combination Therapy 
with Pyronaridine in a P.bergheiANKA-GFP-Luciferase infection. Single dose regimen of 50 
mg/kg pyronaridine tetraphosphate salt administered orally and 250 mg/kg artesunate administered 
via i.p to Balb/cJ female mice (n=3) at time-point 0-hr which corresponds to ~ 10% parasitemia 
confirmed by Giemsa blood film counting. Data is represented as mean ± SEM. One-way analysis of 
variance (ANOVA) *p-value<0.05 
 
Table 5 (a): Measure of Parasite Log Reduction and Duration to Return to initial 





















Artes 250 0.1  2.2 3.8 4.5 0 
Pyr 50 1.4 2.4 4.0 6.1 CURE 3/3 
AS + Pyr 250 + 50 0.5  1.9 3.2 CURE 3/3 
 












Pyr 50 mg/kg + AS 250 mg/kg n=3
LQ
i.P
Pyr 50 mg/kg n=3


















Figure 5 (b): Effect of Increasing Artesunate Dose in a Single Dose Combination Therapy 
with Chloroquine in a P.bergheiANKA-GFP-Luciferase infection. Single dose regimen of 50 
mg/kg chloroquine phosphate salt administered orally and 250 mg/kg artesunate administered via i.p 
to Balb/cJ female mice (n=3) at time-point 0-hr which corresponds to ~ 10% parasitemia confirmed 
by Giemsa blood film counting. Data is represented as mean ± SEM.  
 
Table 5 (b): Measure of Parasite Log Reduction and Duration to Return to initial 





















Artes 250 0.1  2.2 3.8 4.5 0 
CQ 50 0.6 0.9 0.9 2.5 4.8 0 
AS + CQ 250 + 50 0.1  2.0 2.6 7 0 
 












CQ 50 mg/kg + AS 250 mg/kg n=3
CQ 50 mg/kg n=3
LQ
i.P















Figure 5 (c): Effect of Increasing Artesunate Dose in a Single Dose Combination Therapy 
with Amodiaquine in a P.bergheiANKA-GFP-Luciferase infection. Single dose regimen of 50 
mg/kg amodiaquine dihydrochloride salt administered orally and 250 mg/kg artesunate administered 
via i.p to Balb/cJ female mice (n=3) at time-point 0-hr which corresponds to ~ 10% parasitemia 
confirmed by Giemsa blood film counting. Data is represented as mean ± SEM. One-way analysis of 
variance (ANOVA) *p-value<0.05 **p-value<0.001. 
 
Table 5 (c): Measure of Parasite Log Reduction and Duration to Return to initial 





















Artes 250 0.1  2.2 3.8 4.5 0 
AMQ 50 0.9 1.1 1.1 3.1 7 0 
AS + AMQ 250 + 50 0.1  2.3 3.9 9 0 
 














Amq 50 mg/kg n=3
















Figure 5 (d): Effect of Increasing Artesunate Dose in a Single Dose Combination Therapy 
with 4-aminoquinolines in a P.bergheiANKA-GFP-Luciferase infection. Single dose regimen 
of 50 mg/kg 4-aminoquinoline salt administered orally and 250 mg/kg artesunate administered via 
i.p to Balb/cJ female mice (n=3) at time-point  0-hr which corresponds to ~ 10% parasitemia 
confirmed by Giemsa blood film counting. Data is represented as mean ± SEM. ANOVA 
**p<0.001. 
 
Table 5 (d): Measure of Parasite Log Reduction and Duration to Return to initial 


















AS 250 0.1 2.2 3.8 4.5 0 
AS + Pyr 250 + 50 0.5 1.9 3.2 CURE 3/3 
AS + CQ 250 + 50 0.1 2.0 2.6 7 0 
AS + AMQ 250 + 50 0.1 2.3 3.9 9 0 














Amq 50 mg/kg + AS 250 mg/kg n=3
Pyr 50 mg/kg + AS 250 mg/kg n=3
CQ 50 mg/kg + AS 250 mg/kg n=3
















CHAPTER 4 - DISCUSSION 
These studies assessed the in vivo pharmacodynamic properties of artesunate and the 4-
aminoquinolines – pyronaridine, amodiaquine, chloroquine, given in a single dose regimen and also 
evaluated the interaction between artesunate and each of the 4-aminoquinolines in a combination 
therapy. The findings clearly demonstrate that pyronaridine is the most potent of all the antimalarial 
agents tested in this model. Single oral dose pyronaridine ≥ 10 mg/kg is more potent than both 
artesunate administered at single and 3-dose regimen. Artesunate exhibits dose-dependent killing 
when administered at both the single and multi-dose regimens- the higher the dose the longer the 
duration to return to initial parasitemia. Initial dose-independent killing was observed with 
chloroquine and amodiaquine, however there is a similar plateau phase of undetected parasite killing 
observed between 6 hours and 24 hours post initial dose. Dose-independent killing and complete 
cure was achieved with pyronaridine given at single dose ≥ 10 mg/kg. However, partial cure was 
achieved with low dose 7 mg/kg (two-thirds mice cured). Single dose amodiaquine at 250 mg/kg was 
curative (two-thirds mice cured). However, no cure was achieved with chloroquine and artesunate in 
this model. 
We were interested in the viable parasites at 8 and 24 hours after dosing with the long half-
life quinolines. We devised a transfer of washed infected erythrocytes to measure viability and to 
greatly reduce quinoline concentrations. Following the infected blood transfer experiment, we 
measured the duration to reach benchmark parasites per microL. A linearity correlation was observed 
with pyronaridine 50 mg/kg (the higher the parasite log reduction with more time after dosing, the 
longer the days it took to reach viable parasites).  At 24 hours transfer, high dose artesunate took 
nearly the same amount of days to reach viable parasites as single dose pyronaridine 50 mg/kg at 48-
hour transfer. Chloroquine and amodiaquine at both 50 mg/kg single oral dose achieved nearly the 




duration to reaching viable parasites post transfer was not that different, about 1 and 2 days post 8 
and 24 hours transfers respectively.  
Artesunate is short-lived yet acts very rapidly in parasite clearance with nearly 4 log kill 
eliminating the immature ring stage parasites, however the 4-aminoquinolines are long-acting and act 
only by killing mature parasites. Therefore, combination of these two different classes with different 
mechanisms of action will lower risk of drug resistance and recrudescence. (Guatam et al., 2009; Li & 
Weina 2010). To evaluate this, the effect of single dose dynamic killing in combination therapy with 
artesunate and 4-aminoquinolines was assessed. For the combination therapy, the mice groups 
received a single dose of artesunate and 4-aminoquinoline at the same time administered 
intraperitoneally and orally respectively. Chloroquine or amodiaquine 50 mg/kg when given in 
combination with artesunate has an additive interaction and increased parasite log reduction at 24 
hours post dosing compared to CQ or AS given alone. Parasite log reduction was increased to almost 
that of artesunate given alone at 50 mg/kg or 250 mg/kg, clearly shows that pharmacological effect 
of chloroquine or amodiaquine was enhanced by artesunate. Our data findings also showed a slightly 
weak antagonistic interaction between artesunate and pyronaridine combination though it achieved 
cure. Overall, in the second model increasing artesunate dose by 5 fold showed increased killing 
effect for combinations with chloroquine and amodiaquine, increased duration to return to initial 
parasitemia for amodiaquine-artesunate combination and nearly the same duration for chloroquine-
artesunate combination. 
Pyronaridine has been used in China for malaria treatment since 1970 when it was initially 
discovered.  Pyronaridine is readily absorbed and distributed to the tissues following oral 
administration and it is well tolerated and effectively eliminated in the urine. (Park SH and Pradeep K 
2010). Studies utilizing mouse models have strongly and clearly indicated that pyronaridine has high 
efficacy against the asexual blood stages of the Plasmodium parasite. In other studies, it was 




while other studies utilizing P. berghei model have suggested that pyronaridine in combination with 
artesunate allows for lower dose of pyronaridine to be used than when given as monotherapy. In vivo 
clinical studies have shown pyronaridine to be very potent against both P. falciparum parasites and 
chloroquine-resistant strains. However, there has been conflicting data that has been published 
regarding the in vitro activity of pyronaridine in combination with other antimalarial agents. Studies 
have reported weak antagonism, synergistic and additive interactions when pyronaridine is combined 
with artemisinins, additive effect when combined with other 4-aminoquinolines and synergy when 
combined with primaquine. All these conflicting differences might be due to different methods and 
in vivo analyses used. (Chang et al., 1992; Basco et al., 1999; Shao et al., 1984; Vivas et al., 2008; Shao 
1990; Ruscoe et al., 1998; Shao et al., 1992). 
Several studies have assessed the pharmacodynamics drug-drug interactions in vitro and in 
vivo. Particularly for artesunate-pyronaridine combination therapies, there has been conflicting results 
where as some findings showcase antagonistic interactions and others find a synergistic or additive 
interaction. For instance, a group (Vivas et al., 2008) evaluated the efficacy of pyronaridine and 
artesunate, and their studies showed slight antagonism with P. falciparum but the in vivo studies with 
rodent P. berghei found increased activity that suggested additive or synergistic interactions. However 
it is suggested that the combination should be further explored in clinical settings.  
A study by a group (Gupta et al., 2002b) also assessed pharmacodynamic drug-drug 
interactions in combination of artemisinin with 4-aminoquinolines (amodiaquine, pyronaridine and 
chloroquine) tested in three different strains of P. falciparum – one chloroquine-resistant and two 
chloroquine-sensitive strains. They found a synergistic pharmacodynamics interaction between 
artemisinin-amodiaquine and artemisinin-pyronaridine combinations. However, for the chloroquine-
artemisinin combination, their studies found additive pharmacodynamics interaction. Currently, 
artesunate-amodiaquine is one of the first-line recommended ACTs while artesunate-pyronaridine 




endemic areas such as Kenya but it has not yet been recommended by the WHO as one of the ACTs 
for malaria treatment. 
Resistance to pyronaridine has been shown to appear slowly in the field however in 
combination with artesunate the drug resistance is slowed. Clinical studies that have utilized 
pyronaridine monotherapy or combination therapy to treat patients infected with blood stage vivax 
and falciparum malaria have reported pyronaridine to be efficacious for the treatment of the blood 
stage infections. Currently pyronaridine-artesunate (3:1) fixed dose synergistic combination 
(Pyramax®) is used for the treatment of uncomplicated falciparum malaria and blood stage vivax 
malaria (Croft et al., 2012).  
Artemisinin combination therapy is currently considered first line treatment of 
uncomplicated and severe malaria. Drug combination is considered one of the effective ways to 
counteract drug resistance. Therefore, ideal drug partner to artemisinins should exert synergistic or 
additive schizontocidal action. Even though some studies have shown additive interactions between 
pyronaridine and other 4-aminoquinolines, combination of the 4-aminoquinolines alone may not be 
useful in malaria treatment due to the wide spread resistance to these drugs in the malaria endemic 
areas.  
Studying antimalarial interactions between or among drugs used to treat malaria is very 
paramount. Pharmacodynamic interactions do exist between antimalarial drugs as has been shown by 
the in vitro as well as in vivo study models and clinical trials that have assessed additive, synergistic, 
antagonistic combination therapies. However, there’s still more studies need to be done to clearly 
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